MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence

Abstract

These findings reveal a mechanistic basis for observed differences in patient susceptibility to TMZ-driven hypermutation. Furthermore, they establish MGMT promoter methylation level as a potential biomarker to inform clinical management of LGG patients, including monitoring and treatment decisions, by predicting risk of hypermutation at recurrence.